Acute bacterial skin and skin structure infections (ABSSSI) are the skin and soft tissue infections that affect the epidermis, dermis, and subcutaneous tissues. The U.S. FDA defines ABSSSI as lesions with cellulitis/erysipelas, wound infections, and major cutaneous abscesses occurring in a minimum surface area of 75 cm2. Increasing number of ambulatory patients seeking treatment for skin and skin structure infections will further propel growth of the ABSSSI market. For instance, according to Decision Resource Group, in 2014, 11% of 2.7 million hospital admissions for ABSSSI were pediatric patients. The increasing pediatric patient pool is targeted by the manufacturers to enhance its product portfolio with pediatric specific products. For instance, in 2016, Allergan plc received US FDA approval for its supplemental New Drug Application (sNDA) for Teflaro, for ABSSSI indication in pediatric.
Market Dynamics
The major market driver for growth of North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market is increasing research and development activities by pharmaceutical and biopharmaceutical companies to develop new products and novel treatment. For instance, in 2017, Cempra announced promising data from the phase 3 trial of Fusidic acid for the treatment of ABSSSI. In same year, Melinta Therapeutics received U.S. FDA for its product Baxdela, a delafloxacin based ABSSSI medicine, available in both intravenous and oral formulations. Moreover, in 2018, Fresenius Kabi received U.S. FDA approval for new drug application of daptomycin, a lipopeptide class of antibacterial drug, in injectable form for complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactlae etc.
However, misuse of drugs causes antibiotic resistance which is a major factor hindering growth of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market. For example, according to the Centers for Disease Control and Prevention data has shown that treatment indication, choice of agent, or duration of antibiotic therapy is incorrect in 30-50% of cases. Moreover, 30-60% of antibiotics prescribed in intensive care units (ICUs) have been found to be unnecessary, inappropriate, or suboptimal.
Key features of the study:
- This report provides in-depth analysis of the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study are Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, and Sun Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for North America and Europe acute bacterial skin and skin structure infections (ABSSSI) market, research and consulting firms, new entrants, and financial analysts.
Detailed Segmentation:
- North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Route of Administration:
- North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America and Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:
- North America
- By Country:
- U.S.
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Canada
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
- By Country:
- U.K.
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Germany
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Italy
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Spain
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- France
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Russia
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Europe
- By Drug Type:
- Oral & Parenteral Antibiotics
- Vancomycin
- Linezolid
- Clindamycin
- Ceftaroline
- Daptomycin
- Dalbavancin
- Tedizolid
- Others
- Topical Antibiotics
- Hydrogen Peroxide
- Fusidic Acid
- Mupirocin
- Retapamulin
- Povidone-Iodine
- By Infection Type:
- Hospital Acquired ABSSSI
- Community Acquired ABSSSI
- By Route of Administration:
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Merck & Co., Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- GlaxoSmithKline plc.
- Teva Pharmaceutical Industries Ltd.
- Paratek Pharmaceuticals, Inc.
- Melinta Therapeutics, Inc.
- Arrevus, Inc.
- AbbVie Inc.
- Aurobindo Pharma Ltd.
- Amneal Pharmaceuticals LLC
- Sun Pharmaceutical Industries Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
